CASP3 and amyotrophic lateral sclerosis: If this latter mechanism is operative, then the suggested targeting of this protease in ALS or other related neurodegenerative conditions should be approached with caution, as loss of caspase 3 activity may inadvertently lead to aggregate accumulation, exacerbating pathology rather than resolving disease progression.